Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMD-OPTION Phase 2a Study of OMT-28 in Primary Mitochondrial Disease
2022-003307-16Phase 2Active
- Sponsor
- OMEICOS Therapeutics
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of OMT-28 in Mitochondriopathy, myopathies and Cardiomyopathies, sponsored by OMEICOS Therapeutics. Primary endpoint: Responder rate based on GDF-15 reduction. Started Jan 2023; status: active.
02
Drugs
OMT-28
03
Conditions
MitochondriopathymyopathiesCardiomyopathies
Beyond the preview
Go deeper on 2022-003307-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003307-16.